Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312710 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of APG-157 in Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Oropharynx, sponsored by Aveta Biomics.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT05312710: Active Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Oropharynx, sponsored by Aveta Biomics.
NCT05312710 is a Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Oropharynx that is active but no longer recruiting, run by Aveta Biomics. The registered enrollment target is 24 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05312710, a Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Oropharynx, is active but no longer recruiting, sponsored by Aveta Biomics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.
Primary Outcome
Change in Tumor Size from Baseline to end of dosing using MRI with or without contrast and PET/CT imaging.
Conditions Studied
Interventions
- DRUG APG-157
Study Locations (2)
California
- VAGLAHS, West Los Angeles - Los Angeles
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT05312710 still lists
NCT05312710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which APG-157 is the first listed.
NCT05312710 reports a single indexed study location in California, Florida.
Frequently Asked Questions
What is clinical trial NCT05312710 about?
NCT05312710 is a clinical study titled "Safety and Efficacy of APG-157 in Head and Neck Cancer". The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of AP...
What is the current status of trial NCT05312710?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2022-04-22. Estimated completion is 2026-12.
What conditions does trial NCT05312710 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of Oral Cavity.
What interventions are being tested in trial NCT05312710?
The interventions under investigation include: APG-157 (DRUG).
Who is sponsoring clinical trial NCT05312710?
This trial is sponsored by Aveta Biomics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312710 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05312710's enrollment target sits among peer trials
24 205th of 250 higher than 42 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI